Changes in Anti‐HBc Positivity and Antibody Loss in Immunocompromised Patients: An Eight‐Year Hospital‐Based Analysis From a Tertiary Center in Turkey
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.71139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Hasan Zeybek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology, Gulhane Training and Research Hospital, Ankara, Türkiye. Hauptthemen laut MEDLINE: Immunocompromised Host, Hepatitis B Antibodies, Hepatitis B Core Antigens, Hepatitis B, Chronic. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study aimed to evaluate the prevalence of anti‐HBc seropositivity and examine the longitudinal changes in anti‐HBc IgG S/CO reactivity, with particular focus on seroreversion (loss of anti‐HBc antibodies) in immunocompromised patients by correlating laboratory data with clinical history. In this retrospective study (January 2017 and June 2024), serum samples from a tertiary care hospital were tested for hepatitis B serological markers, using chemiluminescent microparticle immunoassay (CMIA). Patients with ≥ 3 anti‐HBc IgG measurements were evaluated for longitudinal monitoring of antibody dynamics. Medical records were reviewed for chronic HBV infection, co‐morbidities, and anti‐HBc loss in immunosuppressed patients. A total of 35,017 clinical samples from 27,758 participants were analysed. In this hospital‐based cohort, the anti‐HBc IgG seropositivity rate was 32.0%. Seropositive individuals were older than seronegatives ( p < 0.001). Longitudinal analyses was performed on 1397 patients with ≥ 3 IgG measurements; consistently 434 remained reactive and 963 remained negative. Linear mixed‐effects analysis showed a significant decline over time (F (1,1679) = 33.65; p < 0.001). Among immunosuppressed patients, 94 initially reactive cases were evaluated; permanent loss occurred in 80.9%. Seroreversion rates were 66.7% in rheumatology, 85.2% in hematology, 100% in oncology, and 69.2% in other departments; massive immunosuppressive cohort (hematology/oncology) had a higher likelihood of seroreversion in an unadjusted, exploratory comparison (OR 3.27; p = 0.04). This study demonstrates time‐dependent decline in anti‐HBc IgG S/CO reactivity. Seroreversion is common in immunocompromised patients. As anti‐HBc reflects past exposure rather than active infection, its loss or negativity in immunosuppressed patients—including seronegative occult HBV infection—means serology alone may give false reassurance. Combined HBsAg/anti‐HBc serology with HBV DNA testing is therefore recommended to detect occult infection and assess reactivation risk in this high‐risk group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology, Gulhane Training and Research Hospital, Ankara, Türkiye.
- Department of Medical Microbiology, Health Sciences University Gulhane Faculty of Medicine, Ankara, Türkiye.
ORCID-Profile: Hasan Zeybek, Tuğrul Hoşbul, Ramazan Gümral, Fatih Şahiner
Zitieren
APA
Zeybek, H., Hoşbul, T., Gümral, R., & Şahiner, F. (2026). Changes in Anti‐HBc Positivity and Antibody Loss in Immunocompromised Patients: An Eight‐Year Hospital‐Based Analysis From a Tertiary Center in Turkey. Journal of Medical Virology. https://doi.org/10.1002/jmv.71139
Vancouver
Zeybek H, Hoşbul T, Gümral R, Şahiner F. Changes in Anti‐HBc Positivity and Antibody Loss in Immunocompromised Patients: An Eight‐Year Hospital‐Based Analysis From a Tertiary Center in Turkey. Journal of Medical Virology. 2026. doi:10.1002/jmv.71139
BibTeX
@article{Zeybek2026,
author = {Zeybek, Hasan and Hoşbul, Tuğrul and Gümral, Ramazan and Şahiner, Fatih},
title = {Changes in Anti‐HBc Positivity and Antibody Loss in Immunocompromised Patients: An Eight‐Year Hospital‐Based Analysis From a Tertiary Center in Turkey},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.71139}
}
EUVIMED